CG Oncology reports Phase 3 PIVOT-006 results showing cretostimogene reduced NMIBC recurrence risk by 68%, supporting a second BLA in 2027.
Written By: Saniya Katakdhond, PharmD
Reviewed By: Pharmacally Editorial Team
CG Oncology reported positive topline results from its Phase 3 PIVOT-006 trial, in which investigational intravesical cretostimogene grenadenorepvec reduced the risk of disease recurrence by 68% compared with surveillance in patients with intermediate-risk non-muscle-invasive bladder cancer (NMIBC). The study met its primary endpoint of recurrence-free survival (RFS) with statistical significance, supporting a planned regulatory expansion into an additional NMIBC population.
Phase 3 Trial Demonstrates Significant Reduction in Recurrence Risk
PIVOT-006 enrolled 367 patients across approximately 90 clinical sites in the United States and Canada to evaluate adjuvant cretostimogene following complete tumor resection. The randomized study compared intravesical cretostimogene against active surveillance, reflecting real-world clinical practice in this setting.
Enrolled patients represented the broad spectrum of disease characteristics defined under American Urological Association (AUA) and Society of Urologic Oncology (SUO) guidelines at study initiation, including:
- Recurrent low-grade (LG) Ta tumors (less than 12 months)
- Solitary LG Ta tumors (greater than 3 cm)
- Multifocal LG Ta tumors
- Solitary high-grade (HG) Ta tumors (3 cm or less)
- Low-grade T1 tumors
At a median follow-up of 17 months as of October 26, 2026, cretostimogene demonstrated a 68% reduction in recurrence risk relative to surveillance, corresponding to a hazard ratio (HR) of 0.32 (95% CI: 0.23–0.45; p less than 0.0001). RFS benefits were observed across both high-grade and low-grade patient subgroups.
According to Vijay Kasturi, M.D., Chief Medical Officer of CG Oncology, reducing recurrence in intermediate-risk and high-grade Ta NMIBC is a critical clinical objective, as disease recurrence often necessitates repeated invasive procedures and adds to ongoing patient burden.
Safety Profile Shows No Grade 3 or Higher Treatment-Related Adverse Events
Cretostimogene demonstrated a favorable safety and tolerability profile consistent with earlier clinical studies. Investigators reported no Grade 3 or higher treatment-related adverse events (TRAEs) and no treatment-related discontinuations.
Oncolytic Immunotherapy Expands NMIBC Development Strategy
Cretostimogene grenadenorepvec is an investigational, intravesically administered oncolytic immunotherapy studied in a clinical program exceeding 700 patients with NMIBC. In addition to PIVOT-006, CG Oncology is evaluating the candidate in the Phase 3 BOND-003 trial for high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive NMIBC—a setting in which cretostimogene holds FDA Fast Track and Breakthrough Therapy designations and is available through a North American Expanded Access Program.
The company is also conducting CORE-008, a multi-cohort trial assessing cretostimogene across BCG-exposed high-risk, BCG-naïve high-risk, and BCG-unresponsive NMIBC populations.
FDA Feedback Broadens Initial BLA; Second Filing Planned for 2027
Following feedback from the FDA, CG Oncology plans to expand its initial biologics license application (BLA) for BCG-unresponsive NMIBC beyond patients with carcinoma in situ (CIS), with or without papillary tumors, to also include patients with high-grade papillary-only disease. To incorporate the additional data, the company now expects to complete this submission by the end of March 2027.
The PIVOT-006 dataset will support a second BLA submission targeting intermediate-risk and high-grade Ta (3 cm or less) NMIBC in the second quarter of 2027. CG Oncology noted that all BLA-enabling manufacturing activities required to support both filings have been completed.
Full topline findings from PIVOT-006 will be presented during a late-breaking podium session at the Society of Urologic Oncology Annual Meeting on December 2, 2026. If supported by the complete dataset and subsequent regulatory review, cretostimogene could become the first FDA-approved adjuvant therapy for an estimated 50,000 patients in the United States with intermediate-risk and high-grade Ta NMIBC.
Cretostimogene remains an investigational therapy, and its safety and efficacy have not been established by the FDA or any other regulatory authority.
Reference
PIVOT-006 Phase 3 Registrational Trial Demonstrates Unprecedented Improvement in Recurrence-Free Survival (RFS) for Intermediate-Risk and High-Grade Ta Non-Muscle Invasive Bladder Cancer (NMIBC), CG Oncology, 16 November 2026
A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT, ClinicalTrials.gov ID NCT06111235
About the Writer
Saniya Sanjay Katakdhond (Linkedin) is a Doctor of Pharmacy professional with hands-on experience in patient case review, clinical documentation, medical record analysis, and patient care.
Her hospital experience has strengthened her understanding of clinical conditions, treatment approaches, and multidisciplinary healthcare practices.
With ICH-GCP certification and a research-oriented approach, she brings clinical insight and attention to detail to healthcare content development.
As a healthcare writer, Saniya focuses on translating clinical knowledge and patient-care experience into clear, accurate, and evidence-informed medical content.
